POMDOCTOR LIMITED Receives Notification Related to NASDAQ's Continued Listing Requirements
Guangzhou, China, November 2, 2026 / PRNewswire / -- POMDOCTOR LIMITED, a digital healthcare company focused on advancing AI enabled healthcare solutions and predictive medical capabilities ("Pomdoctor" or "the Company") ( Nasdaq : POM ), announced today that on October 28, 2026, the Company received two communications ("Communications") from the Listing Qualifications Department ("Staff") of the NASDAQ Stock Market LLC ("NASDAQ") stating that the Company did not meet several ongoing listing requirements of NASDAQ's Global Markets.
The first letter notified the company that, based on the market value of its listed securities from September 16, 2026, to October 27, 2026, over a consecutive period of 30 trading days ( MVLS ), the company no longer met the requirement of maintaining a market value of at least $50 million in listed securities under NASDAQ Listing Rule 5450(b)(2)(A) (" MVLS requirement" ). Staff also indicated that the company did not meet the requirements under NASDAQ Listing Rule 5450(b)(3)(A).
In accordance with NASDAQ Listing Rule 5810(c)(3)(C), the company has a 180-calender-day compliance period, which expires on April 26, 2027, to meet the requirements of MVLS. If at any time during this compliance period, the company's MVLS closes at $50 million or more for at least 10 consecutive trading days, NASDAQ will provide the company with a written confirmation of compliance, and this matter will be closed.
The second letter notified the company that, based on the market value of publicly held shares from September 16, 2026, to October 27, 2026, over a consecutive period of 30 trading days ( MVPHS ), the company no longer met the requirement of maintaining a minimum market value of publicly held shares of $15 million under NASDAQ listing rule 5450(b)(2&3)(C) (" MVPHS requirement" ).
In accordance with NASDAQ Listing Rule 5810(c)(3)(D), the company has a 180-calender-day compliance period, which expires on April 26, 2027, to meet the requirements of MVPHS. If at any time during this compliance period, the company's MVPHS closes at $15 million or more for at least 10 consecutive trading days, NASDAQ will provide the company with a written confirmation of compliance, and this matter will be closed.
If the company fails to comply before the expiration of the applicable compliance period, it will receive a written notice informing it that its securities will face delisting. In such a case, the company may appeal against the delisting decision to an hearing panel.
The company stated that it intends to monitor its MVLS and MVPHS, and assess the available options in order to meet the applicable continuous listing requirements again within the compliance period.
The company stated that it cannot guarantee that it will be able to comply with the applicable Nasdaq continuous listing requirements within the compliance period, or that it will continue to meet other Nasdaq continuous listing requirements in any other manner.
About POMDOCTOR LIMITED
POMDOCTOR LIMITED ( Nasdaq : POM ) is a digital healthcare company dedicated to advancing AI enabled healthcare solutions and expanding predictive healthcare capabilities. The company leverages physician resources, wearable technology, artificial intelligence, healthcare payment networks, and real-world medical data to support more personalized, continuous, and data-driven healthcare services.
Forward-looking statements
This press release contains forward-looking statements. These forward-looking statements include, but are not limited to: the company's ability and plans to restore and maintain compliance with Nasdaq's continuous listing requirements, including MVLS requirements and MVPHS requirements; the company's assessment of alternative options for restoring compliance; and the company's Class A common stocks continuing to be listed on Nasdaq, etc.
Forward-looking statements involve risks and uncertainties, and actual results may differ significantly from those expressed or implied in such statements. Factors that could lead to significant differences in actual results include, but are not limited to: the company's ability to recover and maintain compliance with MVLS requirements, MVPHS requirements, and other ongoing listing requirements of NASDAQ; fluctuations in the market price of the company's Class A common stock; as well as other risks and uncertainties described in the documents submitted by the company to the U.S. Securities and Exchange Commission.
Except as required by applicable laws, the company assumes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this press release.
Investor Relations Contact Information
POMDOCTOR LIMITED
Investor Relations DepartmentEmail: [ email protected ]Ascent Investor Relations LLC
Tina XiaoTelephone: +1-646-932-7242Email: [ email protected ]









